Copyright
©The Author(s) 2019.
World J Gastroenterol. Nov 21, 2019; 25(43): 6373-6385
Published online Nov 21, 2019. doi: 10.3748/wjg.v25.i43.6373
Published online Nov 21, 2019. doi: 10.3748/wjg.v25.i43.6373
n | Tumor | Preopera-tive FLR/ESL-V in % | FLR increase in % | Interval in d | Comple-te planned resection | Major morbidity, ≥ IIIa | PHLF, ≥ B | HM | OS | DFS | ||
Stage I | Stage II | |||||||||||
Case control | ||||||||||||
Schadde et al[3], 2014 | 48/83 | CRLM/HCC/CC | 0.47/0.53b | - | 48 (100)/54 (64) | - | - | |||||
Shindoh et al[4], 2013 | 25/144 | CRLM/HCC/CC | - | 74 (21-192) /62 (0-379) | 9 (5-28) /31 (12-385) | - | 10 (40)/34 (33) | - | 3 (12) /6 (6) | - | - | |
Croome et al[5], 2015 | 15/53 | CRLM/HCC/CC | 20 ± 4/31 ± 14 | 84 ± 8/36 ± 27 | - | 15 (100) /42 (79) | - | - | 2 (13) /12 (23)c | 0/2 (4) | - | - |
Ratti et al[6], 2015 | 12/36 | CRLM | 22/23 | 47/41 | 11/31 | 12 (100) /34 (94.4) | 0/1 (2.8) | 5 (42) /6 (18)d | 0/2 (5.9) | 1 (8.3) /1 (2.9) | 1 yr: 92%/94% | 1 yr: 67%/80% |
Tanaka et al[8], 2015 | 11/54 | CRLM/NET | 34 ± 10/31 ± 10 | 52 (33-94)/22 (34-68)e | - | 11 (100)/48 (89) | 1 (9)/4 (8) | 3 (27)/8 (17) | 5 (45)/5 (9) | 1 (9)/1 (2) | - | - |
Adam et al[9], 2016 | 17/41 | CRLM | 24/30 | 50/33 | 12/103 | 17 (100)/26 (63.4) | 4 (24)/7 (17) | 4 (24)/10 (38) | 0/1 (3.8) | 0/2 (4.9) | 2 yr: 42%/77% | 1 yr: 0%/10% |
Matsuo et al[11], 2016 | 8/14 | CRLM/CC | - | - | 11 ± 2/52 ± 33 | - | 1(13)/4 (29) | 2 (25)/8 (57) | 0/0 | - | - | |
Chia et al[7], 2018 | 10/29 | HCC/ CRLM | 22 (12-29) /22 (15-32) | 48 (39-97)/12 (4-42) | 7 (7-9)/20 (18-29) | 8 (80)/12 (59) | 3 (30)f | 2 (25)g/3 (17.6)h | 2 (25)/0c | 1 (3.4)/0 | - | - |
Meta-analysis | ||||||||||||
Zhou et al[12], 2017 | 201/518 | - | - | WMD +40% | WMD -27% | 97%/73% | OR 2.4i | OR 4.0i | 10%/14% | |||
Randomized controlled trial | ||||||||||||
Sandstrom et al[13], 2018j | 48/49 | CRLM | 22.4 ± 4.3/21.2 ± 5.1 | 68 ± 38/36 ± 18 | 11 ± 11/43 ± 15 | 44 (92)/28 (57) | 19 (43)/12 (43)k | 4 (8.3)/3 (6.1) | 4 (8.3)/3 (6.1) | - | - |
Risk modelling | Risk points | OR (95%CI) |
Pre-stage I variables | ||
CRLM | 0 | 1 |
Non-CRLM/non-biliary | 1 | 1.925 (0.808-4.585) |
Biliary | 2 | 3.767 (1.800-7.822) |
Age ≥ 67 | 3 | 5.668 (2.843-11.300) |
Pre-stage II variables | ||
Pre-stage I score | 0.66 | 1.925 (1.527-2.426) |
Inter-stage complications ≥3b | 1.2 | 3.350 (1.280-8.769) |
Bilirubin | 1.5 | 4.439 (1.699-11.600) |
Creatinine | 1.7 | 5.454 (1.606-18.520) |
n | Tumor | FLR in mL | Hypertrophy | Kinetic growth in %/d | Severe Cx, ≥ IIIB | PHLF, 50-50 | 90-d mortality | |||
Stage I | Stage II | Absolute in mL | Relative in % | |||||||
Case control | ||||||||||
D'Haese et al[38], 2016 | 35/225 | HCC/CRLM | 420 (346-540)/340 (260-433) | 639 (541-855)/617 (487-724) | 206 (172-277)/252 (186-348) | 47 (26-69)/76 (50-108) | 4.7 (2.8-8.9)/9.1 (5.8-14.3) | 14 (27)/54 (17) | 14 (40)/42 (19) | 11 (31)/15 (7) |
Chia et al[43], 2018 | 9/4 | HCC/non-HCC | 381 (280-422)/313 (177-550) | - | 154 (86-166)/251 (248-344) | 40 (22-65)/138 (92-139) | 19 (6-24)/35 (31-39) | 1 (14)/0 | 2 (29)/1 (25) | 1 (11)/0 |
- Citation: Au KP, Chan ACY. Current status of associating liver partition with portal vein ligation for staged hepatectomy: Comparison with two-stage hepatectomy and strategies for better outcomes. World J Gastroenterol 2019; 25(43): 6373-6385
- URL: https://www.wjgnet.com/1007-9327/full/v25/i43/6373.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i43.6373